Bristol-Myers Squibb appoints oncology development head
Dr. Namouni most recently served as head of Medical, leading the worldwide medical organization and prior to that, was the development lead for Yervoy and Opdivo.
Dr. Namouni joined Bristol-Myers Squibb in France in 1999 as life-cycle manager for Taxol and has held positions of increasing responsibility in R&D since. He moved to the U.S. in September 2006 where he became responsible for the development of Erbitux.
Before taking his current role as head of Medical, he was the development lead for Opdivo and Yervoy.
Earlier in his career, Dr. Namouni was a pediatric oncologist at Institut Curie in Paris where his focus was clinical research for the treatment of pediatric tumors.
He received his medical degree from the University of Annaba Medical School in Algeria and his Pediatrics degree from Université Rene Descartes in Paris, France. He also received his Pediatric Oncology and Hematology degree and M.S. in Clinical and Experimental Pharmacology from Université Paris-Sud in France.
Additionally, the company announced that Michael Giordano has retired from Bristol-Myers Squibb after more than 17 years of leadership and service.
Since joining the company, Mr. Giordano and the teams he has led have developed and delivered more than a dozen medicines to patients, marking a successful and distinguished drug development career. ■
What to read next
LATEST MOVES FROM New York
- Actinium Pharmaceuticals appoints Ajit Shetty to board
- Gibraltar Industries promotes Jeffrey Watorek to vice president
- Jim Gianopulos named chairman and CEO of Paramount Pictures
- Acuamark Diagnostics adds Michael Hanbury to board
- Gibraltar Industries appoints Timothy Murphy as CFO
More inside POST
How board political ideology affects CEO pay Leadership